Healthcare provider profile · identity verified

Sandra Elaine Odom

Nurse Practitioner · CASA, AR · NPI 1669933370

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Albuterol Sulfate Hfa	Albuterol Sulfate	167	61
Gabapentin	Gabapentin	149	33
Lisinopril	Lisinopril	141	33
Atorvastatin Calcium	Atorvastatin Calcium	127	32
Levothyroxine Sodium	Levothyroxine Sodium	123	29
Sertraline Hcl	Sertraline Hcl	102	18
Omeprazole	Omeprazole	99	28
Furosemide	Furosemide	98	29
Trazodone Hcl	Trazodone Hcl	98	20
Methylprednisolone	Methylprednisolone	95	87
Potassium Chloride	Potassium Chloride	93	19
Cefdinir	Cefdinir	91	80
Hydrochlorothiazide	Hydrochlorothiazide	88	17
Pantoprazole Sodium	Pantoprazole Sodium	85	24
Amlodipine Besylate	Amlodipine Besylate	78	21
Azithromycin	Azithromycin	76	68
Tizanidine Hcl	Tizanidine Hcl	71	29
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	68	57
Metoprolol Succinate	Metoprolol Succinate	65	15
Buspirone Hcl	Buspirone Hcl	58	11
Rosuvastatin Calcium	Rosuvastatin Calcium	57	16
Meloxicam	Meloxicam	55	20
Tamsulosin Hcl	Tamsulosin Hcl	55	12
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	53	12
Metformin Hcl	Metformin Hcl	53	15
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	52	18
Eliquis	Apixaban	51	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	50	41
Simvastatin	Simvastatin	48	suppressed
Baclofen	Baclofen	47	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	47	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	46	suppressed
Fluconazole	Fluconazole	45	28
Prednisone	Prednisone	45	32
Alprazolam	Alprazolam	44	suppressed
Amoxicillin	Amoxicillin	44	41
Citalopram Hbr	Citalopram Hydrobromide	44	suppressed
Duloxetine Hcl	Duloxetine Hcl	44	suppressed
Sucralfate	Sucralfate	43	14
Metformin Hcl Er	Metformin Hcl	42	13
Metoprolol Tartrate	Metoprolol Tartrate	42	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	39	suppressed
Aripiprazole	Aripiprazole	37	suppressed
Levetiracetam	Levetiracetam	36	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	35	suppressed
Fluticasone Propionate	Fluticasone Propionate	34	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	34	suppressed
Losartan Potassium	Losartan Potassium	33	suppressed
Tramadol Hcl	Tramadol Hcl	33	12
Zolpidem Tartrate	Zolpidem Tartrate	33	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	32	31
Oxybutynin Chloride Er	Oxybutynin Chloride	31	suppressed
Allopurinol	Allopurinol	30	suppressed
Ondansetron Odt	Ondansetron	30	19
Promethazine Hcl	Promethazine Hcl	30	suppressed
Mirtazapine	Mirtazapine	29	suppressed
Spironolactone	Spironolactone	29	suppressed
Carvedilol	Carvedilol	27	suppressed
Divalproex Sodium	Divalproex Sodium	27	suppressed
Entresto	Sacubitril/Valsartan	27	suppressed
Bupropion Xl	Bupropion Hcl	26	suppressed
Clonazepam	Clonazepam	25	suppressed
Estradiol	Estradiol	25	suppressed
Glipizide	Glipizide	25	suppressed
Levofloxacin	Levofloxacin	25	23
Triamcinolone Acetonide	Triamcinolone Acetonide	25	19
Amitriptyline Hcl	Amitriptyline Hcl	24	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	24	suppressed
Jardiance	Empagliflozin	24	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	24	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	24	suppressed
Rexulti	Brexpiprazole	24	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	23	suppressed
Montelukast Sodium	Montelukast Sodium	23	suppressed
Metoclopramide Hcl	Metoclopramide Hcl	22	suppressed
Glimepiride	Glimepiride	21	suppressed
Ropinirole Hcl	Ropinirole Hcl	21	suppressed
Topiramate	Topiramate	21	suppressed
Atenolol	Atenolol	20	suppressed
Naproxen	Naproxen	20	suppressed
Ozempic	Semaglutide	20	suppressed
Breo Ellipta	Fluticasone/Vilanterol	19	suppressed
Diclofenac Sodium	Diclofenac Sodium	19	suppressed
Doxepin Hcl	Doxepin Hcl	19	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	19	suppressed
Metronidazole	Metronidazole	19	15
Pravastatin Sodium	Pravastatin Sodium	19	suppressed
Pregabalin	Pregabalin	19	suppressed
Warfarin Sodium	Warfarin Sodium	19	suppressed
Cephalexin	Cephalexin	18	18
Ciprofloxacin Hcl	Ciprofloxacin Hcl	18	16
Mounjaro	Tirzepatide	18	suppressed
Ondansetron Hcl	Ondansetron Hcl	18	12
Ceftriaxone	Ceftriaxone Sodium	17	11
Premarin	Estrogens, Conjugated	17	suppressed
Lidocaine Hcl	Lidocaine Hcl	16	11
Clopidogrel	Clopidogrel Bisulfate	15	suppressed
Januvia	Sitagliptin Phosphate	15	suppressed
Ketoconazole	Ketoconazole	15	suppressed
Lantus	Insulin Glargine,hum.Rec.Anlog	15	suppressed
Fenofibrate	Fenofibrate	14	suppressed
Finasteride	Finasteride	14	suppressed
Mupirocin	Mupirocin	14	13
Neomycin-Polymyxin-Dexameth	Neomycin/Polymyxin B/Dexametha	14	13
Glipizide Er	Glipizide	13	suppressed
Nitroglycerin	Nitroglycerin	13	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	12	12
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	12	suppressed
Ibandronate Sodium	Ibandronate Sodium	12	suppressed
Valacyclovir	Valacyclovir Hcl	12	suppressed
Victoza 3-Pak	Liraglutide	12	suppressed
Dexamethasone	Dexamethasone	11	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	11	suppressed
Lamotrigine	Lamotrigine	11	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	11	suppressed
Nabumetone	Nabumetone	11	suppressed
Valsartan	Valsartan	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error